Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propoxyphene
Drug ID BADD_D01865
Description Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Indications and Usage For the relief of mild to moderate pain.
Marketing Status approved; illicit; investigational; withdrawn
ATC Code N02AC04
DrugBank ID DB00647
KEGG ID D00482; D07809
MeSH ID D011431
PubChem ID 10100
TTD Drug ID D0D4PB
NDC Product Code Not Available
UNII S2F83W92TK
Synonyms Dextropropoxyphene | Propoxyphene | D-Propoxyphene | D Propoxyphene | Propoxyphene Hydrochloride | Hydrochloride, Propoxyphene | Propoxyphene Hydrochloride, (R*,R*)-(+-)-Isomer | Propoxyphene Sulfate, (S-(R*,S*))-Isomer | Propoxyphene Hydrochloride, (R-(R*,S*))-Isomer | Propoxyphene Hydrochloride, (S-(R*,R*))-Isomer | Propoxyphene Maleate, (+)-Isomer | Propoxyphene Phosphate, (S-(R*,S*))-Isomer | Darvon | Propoxyphene Hydrochloride, (R-(R*,R*))-Isomer
Chemical Information
Molecular Formula C22H29NO2
CAS Registry Number 469-62-5
SMILES CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic steatosis09.01.07.003; 14.08.04.005---
Hepatocellular injury09.01.07.008---
Hepatomegaly09.01.05.001---
Hip fracture12.04.01.001; 15.08.03.001--
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Liver function test abnormal13.03.04.030---
Loss of consciousness17.02.04.004---
Metabolic acidosis14.01.01.003---
Myocardial infarction02.02.02.007; 24.04.04.009--
Myopathy15.05.05.001---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Pancreatitis acute07.18.01.002---
Rash23.03.13.001---
Respiratory arrest22.02.01.009---
Respiratory depression17.02.05.047; 22.02.01.010---
Seizure17.12.03.001--
Shock24.06.02.002---
Somnolence17.02.04.006; 19.02.05.003--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Drug tolerance08.06.01.003---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages